




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12Q 1/68</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/45554</b> <b>(43) International Publication Date:</b> 4 December 1997 (04.12.97)
<b>(21) International Application Number:</b> PCT/GB97/01487 <b>(22) International Filing Date:</b> 2 June 1997 (02.06.97) <b>(30) Priority Data:</b> 60/018,748 31 May 1996 (31.05.96) US <b>(71) Applicant:</b> MOLECULAR SCIENCES LIMITED [GB/GB]; The Cedars, Watermill Lane, East Sussex TN34 4HY (GB). <b>(72) Inventors:</b> BRUCE, Ian, James; The Cedars, Watermill Lane, Pett, East Sussex TN35 4HY (GB). DAVIES, Martin, J.; 37 Ullswater Close, Bromley, Kent BR1 4JF (GB). <b>(74) Agent:</b> EDWARD EVANS & CO.; Chancery House, 53-64 Chancery Lane, London WC2A 1SD (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> CAPTURE OF SINGLE STRANDED NUCLEIC ACIDS  <b>(57) Abstract</b>  A solid phase substrate derivatized with single stranded nucleic acids having random sequences of nucleotide bases and related method of capturing one or more single stranded nucleic acids by contacting with the solid phase substrate wherein the single stranded nucleic acids anneal to the nucleic acids of the substrate to result in the captured sequences.   <p><b>AMPLIFICATION REACTION</b></p> <p><b>CAPTURE OF SINGLE STRANDED NUCLEIC ACIDS</b></p> <p><b>REMOVAL OF CAPTURED SEQUENCES</b></p> <p><b>ASSAY AMPLIFICATION PRODUCT</b></p> <p><b>PRIMER</b></p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CAPTURE OF SINGLE STRANDED NUCLEIC ACIDS

## FIELD OF THE INVENTION

The present invention relates to solid phase supports or  
10 substrates for use in the capture of single stranded nucleic  
acids. The invention also relates to a method of capturing  
single stranded nucleic acids using such supports or  
substrates. In particular, but not exclusively, the invention  
relates to the use of magnetic solid phase supports for  
15 capturing PCR (polymerase chain reaction) primers.

## BACKGROUND OF THE INVENTION

PCR and other amplification methods offer the best option  
for sensitive, reliable, cheap and easy detection,  
characterization, quantitation and discrimination of nucleic  
20 acid sequences. A few copies of template target nucleic acid  
can be replicated in vitro or in situ to provide enough  
product nucleic acid for analysis. However, the end product  
often has to be separated and purified from the reaction  
mixture before its identification and characterization is  
25 possible, and whilst amplification can be rapid,  
identification and characterization can be slow and laborious.  
The characterization and identification of the nucleic acid  
amplification product represents a considerable bottleneck in  
the processing of samples particularly in diagnostic  
30 applications of amplification methodologies. For this reason  
quicker and more convenient methods are desirable for

amplification product detection and characterization to improve high throughput screening of biological samples.

With respect to amplification product detection, it is known that PCR products, either modified or unmodified, can be identified and characterized spectrophotometrically. However, determination of the amplification product can be difficult or impossible in the presence of modified or unmodified excess primers present in the reaction mixture at completion of amplification. It is necessary to be able to discriminate between these two species (i.e. amplification products and primers) to permit product detection and characterization, on line, at the end of the amplification process.

In view of the above it is known that single stranded nucleic acid sequences complementary to other nucleic acids can be used to 'capture', by hybridization, such other sequences and that these capture sequences can be derivatized to a support. Such a support (hereinafter known as 'the support') could be a magnetizable or non-magnetizable particle or bead, porous or non-porous membrane, microtitre plate, paper or surface or substrate material that may be contacted with a fluid medium.

Techniques currently exist which make use of these principles. It is possible to detect and characterize a PCR product by its denaturation and subsequent 'capture' to a complementary single stranded oligonucleotide immobilized to a support. The support is frequently represented by a microtitre plate; the single stranded capture sequences are bound to the wall of the wells of the plate and are used to hybridize to a denatured, single stranded amplification product. Excess primers are removed from the system by washing the bound product in the microtitre plate wells, and the amplification product is subsequently detected and characterized by spectrophotometric means. However these techniques are frequently time consuming and complex and risk introducing contamination and artefacts into the process.

An alternative approach would be to remove excess primers from the amplification reaction mixture subsequent to amplification and determine the amplification product directly in solution spectrophotometrically. This would have the benefit of being a potentially faster simpler and more efficient process for amplification product/primer separation and detection and characterization. In the present invention such benefits and advantages over known prior art procedures are provided by a substrate/support where separation, detection and characterization of amplification products are analyzed spectrophotometrically in solution.

Surprisingly we have observed that a magnetizable solid phase support (MSPS) derivatized with single stranded nucleic acids having random sequences of nucleotide bases can anneal to and thereby capture single stranded nucleic acids as effectively as capture sequences having nucleotide sequences complementary to those to be captured. This discovery is applicable to the capture of all single stranded nucleic acid species including PCR primers. Essentially this discovery indicates that complementarity between single stranded nucleic acid capture sequences and the sequence to be captured is unnecessary to effect the latter's capture. We have surprisingly observed that a mixture of totally random sequences, present as oligonucleotides, derivatized to a support can function as well as specific, complementary capture sequences in the removal of single stranded nucleic acids from solution, including primers from PCR reaction mixtures.

#### SUMMARY OF THE INVENTION

In the present invention, these purposes, as well as others which will be apparent, are achieved generally by providing a solid phase substrate or support derivatized with single stranded nucleic acids having random sequences of nucleotide bases and related method of manufacture. The

substrate/support is preferably magnetizable, but any structure capable of attaching the random sequences of nucleotide bases can be used in the invention.

5 The random sequences of nucleotide bases are prepared by automated synthesis and are preferably 20 to 30 nucleotides long, most preferably 25. However, in accordance with the invention, both shorter and longer sequences also work, for example, random capture sequences as short as 5 nucleotides and as long as 175 nucleotides, which is the upper limit for  
10 automated synthesis, can be used. Random sequences longer than 175 bases, made by ligation, can also be used. Prior to attachment to the substrate these sequences are further modified with materials to facilitate addition to the support, such materials include biotin or a primary amine group. The  
15 substrate is also modified to promote such addition. To permit conjugation with the biotinylated nucleic acid sequences the support is derivatized with streptavidin. The substrate is also derivatized with carboxymethyl groups which are conjugated to the primary amine group. Both modifications  
20 provide means of attachment of the random sequences to the substrate/support which is then used to capture single stranded nucleic acids in amplification processes.

The invention also provides a method of capturing one or more single stranded nucleic acids by addition of the solid  
25 phase substrate derivatized with single stranded nucleic acids having random sequences of nucleotide bases to a fluid medium containing both single stranded and double stranded nucleic acids. The single stranded nucleic acids anneal to the nucleic acids of the substrate to result in the captured  
30 sequences.

In the embodiment where the substrate is magnetizable, the substrate with the captured sequences is removed by a magnet from the fluid medium to form a medium free of the substrate. This medium is then assayed for the presence of

double stranded nucleic acids which have not annealed to the nucleic acids of the substrate.

The captured sequences are single stranded nucleic acids selected from the group consisting of oligonucleotides, polynucleotides and nucleic acid bases. Preferably, the captured sequences are primers, particularly polymerase chain reaction primers, used in nucleic acid amplification reactions.

In addition the primers and their amplification products produced can be made fluorescent by attaching a label to the 5'-terminus of the primer or attached to a nucleotide base of the primer. The labels used in the invention process include fluorochrome or a primary amine group and are preferably in the form of its N-hydroxysuccinimide ester or its isothiocyanate derivative.

Encompassing the various aspects of the invention a method for assaying double stranded nucleic acids is provided. The process includes treatment of a fluid medium containing single and double stranded nucleic acids with the magnetizable solid phase substrate derivatized with single stranded nucleic acids having random sequences of nucleotide bases causing the single stranded nucleic acids to anneal to the nucleic acids of the substrate to result in the captured sequences. The captured sequences are removed with a magnet to form a medium free of substrate and assaying the medium for the presence of double stranded nucleic acids which have not annealed to the nucleic acids of said substrate.

Other objects, features and advantages of the present invention will be apparent when the detailed description of the preferred embodiments of the invention are considered in conjunction with the drawings, which should be construed in an illustrative and not limiting sense as follows:

## BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a graphic illustration of the solid phase substrate of the invention showing attachment of the random capture sequence to the support;

5       FIGURE 2A is a graphic illustration of the attachment of the random capture sequences to the substrate, where the support is derivatized with materials 12, such as streptavidin or carboxymethyl groups, to attach the random sequences;

10       FIGURE 2B represents the modification of the random capture sequence with a function 8, such as biotin or a primary amine group, for attachment to the support;

FIGURE 3A is a schematic representation of the invention process of capturing single stranded nucleic acids; and

15       FIGURE 3B represents the modification of the primer sequence with a label, such as a fluorochrome or primary amine.

## DETAILED DESCRIPTION OF THE INVENTION

As used throughout the specification the terms substrate and support are used interchangeably and are meant to refer to  
20       the same feature of the invention. Both the substrate and support provide the structure for attachment of the random sequences of nucleotide bases.

In accordance with a first aspect of the invention and as illustrated in FIGURE 1, there is provided a solid phase  
25       support or substrate 2 derivatised with single stranded nucleic acids having random sequences of nucleotide bases 4.

The random sequences of nucleotide bases 4 derivatised to the support 2 may be referred to as 'random capture sequences' and are attached to the support at their 5' or 3'-terminus, or  
30       at one or more of the nucleotide bases of the single stranded nucleotides. Preferably, the random capture sequences are attached to the support at their 5'-terminus. It is to be understood that the single stranded nucleic acids may be

composed partially or entirely of random sequences of nucleotides.

In accordance with a second aspect of the invention and as illustrated in FIGURE 3A, there is provided a method of capturing one or more single stranded nucleic acids 18, comprising contacting a fluid medium 14 containing such nucleic acids with a support derivatised with single stranded nucleic acids having random sequences of nucleotide bases 10 whereby the one or more single stranded nucleic acids anneal to the nucleic acids with which the solid phase support is derivatised 20.

The one or more single stranded nucleic acids to be captured may be oligonucleotides, polynucleotides or longer 18. Especially, the single stranded nucleic acids may be primers used in nucleic acid amplification reactions, such as PCR primers.

The solid phase support 2 may be a magnetizable solid phase support (MSPS) which by means of a magnet may be removed from the medium or concentrated and immobilized in a portion of the medium leaving the remainder of the medium free of the support, to enable the medium or the remainder of the medium to be assayed (e.g. by spectrophotometric means) for the presence of nucleic acids which have not annealed to the nucleic acid with which the support has been derivatized. In this way, when PCR has been effected, the amplification product 16 can be left in solution and is assayable by spectrophotometric means.

In addition, this method can be further modified by labeling the primers used in the amplification reaction at their 5'-terminus thereby making them and their products fluorescent. This embodiment is described and illustrated in Examples 2 through 4 herein. Alternatively, the primers may also be labeled at one of their nucleotide bases.

The random capture sequences for derivatizing the support may be prepared by automated synthesis, according to

procedures as known in the art, and can be from 5 to over 175 nucleotides long. Preferably the random sequences are between 20 to 30 nucleotides long, most preferably about 25. Although the upper limit for automated synthesis is 175 bases, longer  
5 sequences can be obtained by ligation.

In the preparation of random capture sequences, as illustrated in FIGURE 2B, a function that enables the sequence to be attached to the solid phase support is also required to be present on the sequence. For example, the function may be  
10 biotin or a primary amine group. The function may be introduced at the 5'-terminus or the 3'-terminus of the random capture sequences or it may be introduced at one or more of the nucleotide bases of the random capture sequences. In particular, it may be introduced at the 5'-terminus.

As illustrated in FIGURE 2A, the support may be derivatised with the random capture sequences by being conjugated thereto in accordance with standard procedures 12. For example the support may be derivatised with streptavidin  
15 12 to permit conjugation with biotinylated random capture sequences. Alternatively, the support may be derivatised with carboxymethyl groups 12 according to standard procedures, and the carboxymethyl groups can be conjugated to random capture  
20 sequences possessing a primary amine group at the 5'-terminus, using known methods.

25 The primers used in the amplification reactions may also be prepared by automated synthesis, according to procedures as known in the art.

As illustrated in FIGURE 3B, if a label 22, or a function to which a label can be attached, is introduced at the 5'-  
30 terminus of the primer 18 during automated synthesis, then this can improve the opportunity for subsequent spectrophotometric detection of the amplification product. The label or function introduced at the 5'-terminus may be, for example, a fluorochrome or biotin. Alternatively, the

label may be introduced at one of the nucleotide bases of the primer.

5 The function to which a label may be attached at the 5'-terminus of a synthetic oligonucleotide (primer) is commonly a primary amine group. A label such as that referred to above may be attached to this primary amine group and should be ideally in the form of its N-hydroxysuccinimide (NHS) ester or isothiocyanate (ITC) derivative, which can be attached using known methods.

10 The following examples illustrate the invention. Example 1 describes the preparation of solid phase substrates for use in the capture of single stranded nucleic acids. Example 2 describes primer solutions treated with substrates of Example 1 having random capture sequences compared with treatment with  
15 specific capture sequences complementary to the primer sequences. Examples 3 and 4 illustrate use of the invention substrates in PCR amplification reactions. These examples are merely representative and are not inclusive of all the possible embodiments of the invention.

20 EXAMPLE 1

Solid phase supports, in accordance with the invention, for use in the capture of single stranded nucleic acids were prepared. Random capture sequences 25 bases in length were synthesized by 24 consecutive additions of mixed AGCT  
25 phosphoramidites to a mixed AGCT column, prepared by mixing equal amounts of controlled pore glass (CPG) support from individual columns of CPG-A, CPG-C, CPG-T and CPG-G and repacking in a column assembly.

Although the random sequences prepared in accordance with  
30 this example are 25 bases in length, these sequences are only representative, not limiting, to the invention. The random capture sequences of the invention are from 5 to over 175 nucleotides long. Preferably 20 to 30, most preferably 25.

The sequences of the invention are totally random. They are undefined and unknown. They are prepared in accordance with the protocol above by automated synthesis, as known in the art. Specifically, the random sequences are prepared by  
5 consecutive additions of equal volume aliquots from a single vessel containing a mixture of A, G, C and T phosphoramidites (supplied by Perkin Elmer Labs, Foster City, California), which are mixed in proportions that ensure equal reactivity of each, such that there is an equal chance of each A, G, C or T  
10 phosphoramidite becoming attached to the terminus of the sequence as it is synthesized.

The 3'-terminus CPG (controlled pore glass) support is prepared by mixing A-CPG, G-CPG, T-CPG and C-CPG taken from individual columns, in equal amounts, in a single column  
15 assembly, and carrying out the subsequent consecutive additions of mixed A/G/C/T phosphoramidites to this. The total number of possible sequences that can be prepared, according to the example, is  $4^{n/2}$ .

"Specific" capture sequences complementary to the forward  
20 and reverse primer sequences given in Examples 2 to 4 below, were similarly synthesized but using a selected A, G, C or T phosphoramidite in each addition. All capture sequences were prepared with a 5'-biotinylated terminus introduced at the final step of the automated synthesis.

25 5'-biotinylated capture sequences of 25 nucleotide bases' length were bound to streptavidin-coated paramagnetic beads (Dynal Ltd, Wirral, United Kingdom) in high salt buffer (1M NaCl, 10mM tris.HCL, 1mM EDTA, pH8) according to the manufacturer's protocol. The resulting supports were stored  
30 in sterile distilled water at a concentration of 10mg ml<sup>-1</sup>, at 4°C. These supports, unless otherwise indicated, were used in the Examples below.

## EXAMPLE 2

Primer sequence solutions were treated with the invention supports having random capture sequences as prepared in Example 1 and were also treated with "specific" capture sequences complementary to the forward and reverse primer sequences. The following protocol was followed.

Two 50 $\mu$ l aliquots of a solution containing 0.2 $\mu$ M each of the Eco RY13 forward and reverse primers listed below (Sequence ID Nos. 1 and 2), which were labelled at their 5'-terminus with rhodamine, were diluted with 50 $\mu$ l of 20X SSPE buffer (2.98M NaCl/0.23 NaH<sub>2</sub>PO<sub>4</sub>/0.02M EDTA) and added to 0.5mg and 1.0mg, respectively, of support (pre drained) derivatised with random capture sequences as described in Example 1. The Eco RY13 forward and reverse primers are well known in the art.

### Escherichia coli RY13 Primer Sequences:

5'-GCTCTTAGCAACGAATACCCTCAAT 3' (forward); SEQ. ID No. 1  
5'-ACAAGTCACGCCCCAACACTCTGA-3' (reverse); SEQ. ID No. 2

A ligand loading of 200pmol of primer per milligram of support was used. This amount represents the amount of derivatized group present on the support. Each suspension was mixed gently at 22°C for periods up to 10 min, the support was immobilized using a magnet, the supernatants from each removed, and its fluorescence determined.

As a comparison, a further 50 $\mu$ l aliquot of the same primer solution was taken and diluted with 50 $\mu$ l of 20X SSPE buffer, and added to 0.5mg of supports derivatised with specific capture sequences complementary to the Eco RY13 primer sequences. The suspension was mixed, and the supernatant removed and analyzed as before.

All fluorescence measurements were performed using a Jenway 6200 fluorimeter (Jenway Ltd. Dunmow, United Kingdom) in a 45 $\mu$ l quartz fluorimetry cuvette (Helma Ltd, Westcliffe-

on-Sea, United Kingdom). The fluorescence of the stock primer solution before primer removal was scaled to 100 arbitrary fluorescence units; a blank reading scaled to zero was taken using 1:1 water: 20X SSPE. An excitation wavelength of 546nm and emission detection wavelength of 589nm were used.

TABLE I

Capture supports/mg (Type of capture sequence)	Incubation Time (min)		
	2	5	10
	Fluorescence		
0.5 (specific)	18	16	16
0.5 (random)	41	37	33
1.0 (random)	30	20	16

TABLE I illustrates the fluorescence remaining after capture of 5'-rhodamine labelled EcoRI primers by specific and random sequences immobilized to paramagnetic supports. The support with captured sequences were removed by magnets with the remaining supernatant being analyzed. Readings are in arbitrary fluorescence units. Stock solution of primers was scaled to 100 units. These represent average results from 3 identical experiments.

As shown in TABLE I, it is seen that 1mg of random sequence capture supports removes practically as much labelled primer from solution as does 0.5mg of specific, complementary sequence supports. 0.5mg of random sequence supports captures less labelled primer than 0.5mg of specific, complementary supports.

It should be noted that in a control experiment where the labelled primers were incubated with Dynal beads not derivatised with oligonucleotide capture sequences, the amount of fluorescently labelled primer removed was less than 5% of the total initially present.

EXAMPLE 3

This example illustrates the use of the invention substrates in a PCR amplification reaction.

5 A PCR amplification of a 680 base-pair region of the DNA sequence encoding the restriction enzyme *EcoRI* (the sequence of which is well known in the art) was performed using the *EcoRI* primers (Sequence ID Nos. 1 and 2) listed in Example 2, using the following protocol.

10 PCR reaction mixtures contained reaction buffer (10mM Tris-HCl, 1.5mM magnesium chloride, 50mM KCl, pH 8.3), 200 $\mu$ M (each) deoxynucleotide triphosphates, 0.2 $\mu$ M each primer, 2 units *Taq* DNA polymerase (Boehringer Mannheim Limited), 100ng template DNA and deionized water to a final volume of 100 $\mu$ l.

15 PCR amplification was performed using a Techne PHC-3 Thermal Cycler (Techne (Cambridge) Limited, Duxford, United Kingdom) using the following conditions: initial heat denaturation at 94°C for 5 min and annealing for 1min at 55°C and then 30 cycles of heat denaturation at 94°C for 1 min, primer annealing at 55°C for 1 min and DNA extension at 72°C  
20 for 1 min. A final extension at 72°C for 5 min was also performed. Both primers were labelled at their 5'-terminus with rhodamine.

25 Two 50 $\mu$ l aliquots of the PCR amplification mixture were taken, diluted with 20X SSPE, and incubated as described in Example 2 with 0.5mg, and 1.0mg, respectively, of random sequence capture supports, and 0.5mg of specific, complementary sequence capture supports. The fluorescence remaining in the supernatants was determined as before in Example 2 and summarized below in TABLE II.

TABLE II

Support/mg (Type of capture sequence)	Incubation time/min	Fluorescence remaining after incubation with beads
0.5 (specific)	5	44
0.5 (random)	5	79
1.0 (random)	10	45

TABLE II illustrates the comparison of capture of 5'-rhodamine labelled EcoRI primers from PCR mixtures by specific and random sequences immobilized to paramagnetic supports, following amplification of EcoRI restriction enzyme sequence. The support with captured sequences were removed by magnets with the remaining supernatant being analyzed. Amplification mixture was scaled to 100 arbitrary fluorescence units. These figures represent average results from 3 identical experiments.

As shown in TABLE II, it is seen that 1 mg of random sequence supports removes practically as much fluorescent primer from solution as does 0.5 mg of specific, complementary sequence supports.

The remaining supernatants were analyzed by agarose gel electrophoresis. Although fluorescently labelled primers were used in the amplification process, no bands due to fluorescent primers were observed in the supernatant remaining after incubation with the random sequence supports by UV transillumination and autofluorescence, or by ethidium bromide staining followed by UV transillumination.

#### EXAMPLE 4

This example illustrates the use of the invention substrates in a PCR amplification reaction.

A PCR amplification of 559 base-pair sequence of the coding region of the *Legionella pneumophila* macrophage infectivity potentiator (mip) gene was performed, using the primers listed below (Sequence ID Nos. 3 and 4), which were labelled at their 5'-terminus with rhodamine. Sequence ID No. 3 represents *Legionella pneumophila* upper (forward) primer and Sequence ID No. 4 represents *Legionella pneumophila* lower (reverse) primer. The sequences of this gene and primers are well known in the art.

10 *Legionella pneumophila* Primer Sequences:

LPU: 5'-GCTACAGACAAGGATAAGTTG-3'; SEQ. ID No. 3

LPL: 5'-GTTTTGTATGACTTTAATTCA-3'; SEQ. ID No. 4

15 Amplification was performed according to the protocol as set forth in Example 1. Capture of excess primers was carried out using random sequence capture supports according to Example 2, except a ligand loading of 40pmol of oligonucleotide per milligram of support was used, and incubation was for 30 min at 65°C.

20 Fluorimetric analysis was performed as described in preceding Examples 2 and 3.

25 PCR products and excess primers were also separated and recovered for assay from agarose gels. 20µl of a PCR mixture after thermal cycling was loaded into a well of 1.5% low melting temperature agarose gel (NuSieve GTG Agarose, FMC BioProducts, United States of America) and electrophoresed in TBE buffer (0.089M Tris·HCL 0.089M boric acid, 0.002M EDTA, pH 8.0) at 7Vcm<sup>-1</sup> for 2 hours. Gels were subsequently visualized on a UV transilluminator and fluorescent product and primer bands excised using a sterile scalpel blade. The product/primer gel slice (approximately 50µl) was diluted with 300µl of sterile distilled water and dissolved by heating.

30 TABLE III below summarizes the fluorimetric analysis and illustrates the comparison of separation of 5'-rhodamine

labelled *L.Pneumophila* primers from PCR mixtures by random sequence capture paramagnetic supports and agarose gel electrophoresis, following amplification of 659bp sequence of the *mip* gene. The amplification mixture was scaled to 100 arbitrary fluorescence units. These figures represent average results from 3 identical experiments.

TABLE III

10	Method of Separation	Fluorescence due to product	Fluorescence due to primers
	Random sequence magnetic capture support	26	74
15	Agarose gel electrophoresis	27	59

With reference to TABLE III it is seen that the values obtained for fluorescence generated by the PCR product alone are in close accord with that which was observed to be left in solution after incubation with the random capture supports, which implies that the fluorescence remaining in solution is entirely due to double stranded PCR product. This is also confirmed by the elution and fluorescence analysis of the excess primer band which gave a fluorescence value equal to 100 arbitrary fluorescence units minus that of the product fluorescence.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: Davies, Martin J.  
Bruce, Ian James

(ii) TITLE OF INVENTION: CAPTURE OF SINGLE STRANDED  
NUCLEIC ACIDS

(iii) NUMBER OF SEQUENCES: 4

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTCTTAGCA ACGAATACCC TCAAT

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AACAAGTCAC GCCCCAACAC TCTGA

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCTACAGACA AGGATAAGTT G

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTTTTGTATG ACTTTAATTC A

## CLAIMS

1. A solid phase support or substrate derivatised with single stranded nucleic acids having random sequences of nucleotide bases.
2. A solid phase support or substrate according to claim 1, being a magnetisable solid phase support or substrate.
3. A solid phase support or substrate according to claim 1, wherein the single stranded nucleic acids are attached to the solid phase support or substrate at their 5' or 3'-terminus, or at one or more of the nucleotide bases of the single stranded nucleic acids.
4. A solid phase support or substrate according to claim 1 wherein biotin is attached at the 5' or 3'-terminus of the nucleic acids with which the support or substrate is derivatised, or at one or more of the nucleotide bases of the single stranded nucleic acids.
5. A solid phase support or substrate according to claim 4, wherein the support is derivatised with streptavidin to permit conjugation with the biotinylated nucleic acids.
6. A solid phase support or substrate according to claim 1, wherein a primary amine group has been introduced at the 5' or 3'-terminus of the nucleic acids with which the support is derivatised, or at one or more of the nucleotide bases of the single stranded nucleic acids.

7. A solid phase support or substrate according to claim 6, wherein the support or substrate is derivatised with carboxymethyl groups and the carboxymethyl groups conjugated to the primary amine.
8. A method of preparing a solid phase support or substrate comprising derivatising the support or substrate with nucleic acids having random sequences of nucleotide bases.
9. A method according to claim 8, wherein the nucleic acids having random sequences of nucleotide bases are prepared by automated synthesis.
10. A method according to claim 8, wherein the solid phase support is magnetisable solid phase support or substrate.
11. A method according to claim 8, wherein biotin is attached at the 5' or 3'-terminus of the nucleic acids with which the support or substrate is derivatised, or at one or more of the nucleotide bases of the single stranded nucleic acids.
12. A method according to claim 11, wherein the support or substrate is derivatised with streptavidin to permit conjugation with the biotinylated nucleic acids with which the support or substrate is to be derivatised.
13. A method according to claim 8, wherein a primary amine group is introduced at the 5' or 3'-terminus of the nucleic acids with which the support is to be derivatised, or at one or more of the nucleotide bases of the single stranded nucleic acids.

14. A method according to claim 13, wherein the support or substrate is derivatised with carboxymethyl groups and the carboxymethyl groups conjugated to the primary amine group.
15. A method of capturing one or more single stranded nucleic acids, comprising contacting a fluid medium containing such nucleic acids with a solid phase support or substrate derivatised with single stranded nucleic acids having random sequences of nucleotide bases whereby the former one or more single stranded nucleic acids anneal to the nucleic acids with which the solid phase support is derivatised.
16. A method according to claim 14, wherein the solid phase support or substrate is a magnetisable solid phase support or substrate and, after the former single stranded nucleic acids have annealed to the nucleic acids with which the support or substrate is derivatised, the magnetisable solid phase support or substrate is, by means of a magnet, removed from the medium or concentrated and immobilized in a portion of the medium leaving the remainder of the medium free of the support or substrate, whereby the medium or the remainder the medium can be assayed for the presence of nucleic acids which have not annealed to the nucleic acids with which the support has been derivatised.
17. A method according to claim 15, wherein the one or more single stranded nucleic acids to be captured are oligonucleotides, polynucleotides or longer.
18. A method according to claim 17, wherein the single stranded nucleic acids to be captured are primers used in nucleic acid amplification reactions.

19. A method according to claim 18, wherein the one or more single stranded nucleic acids to be captured are PCR primers.
20. A method according to claim 18, wherein the primers and thereby their amplification products are made fluorescent through 5'-modification.
21. A method according to claim 15, wherein the single stranded nucleic acids with which the support or substrate is derivatised have been prepared by automated synthesis.
22. A method according to claim 15, wherein the single stranded nucleic acids to be captured have been prepared by automated synthesis.
23. A method according to claim 18, wherein a label or a function to which a label can be attached is introduced at the 5'-terminus of the primer whereby the amplification product can be detected spectrophotometrically.
24. A method according to claim 23, wherein the label or function introduced at the 5'-terminus of the primer is a fluorochrome.
25. A method according to claim 23, wherein the function is a primary amine group.
26. A method according to claim 23, wherein the label is in the form of its N-hydroxysuccinimide ester or its isothiocyanate derivative.

27. A method according to claim 15, wherein biotin is introduced at the 5'-terminus of the nucleic acids with which the support or substrate is to be derivatised.
28. A method according to claim 27, wherein the support or substrate has been derivatised with streptavidin to permit conjugation with the biotinylated nucleic acids with which the support or substrate is derivatised.
29. A method according to claim 15, wherein a primary amine group has been introduced at the 5'-terminus of the nucleic acids with which the support is derivatised.
30. A method according to claim 29, wherein the support or substrate has been derivatised with carboxymethyl groups and the carboxymethyl groups are conjugated to the primary amine group introduced at the 5' or 3'-terminus of the single stranded nucleic acid, or at one or more of the nucleotide bases.
31. A method of assaying double stranded nucleic acids in a medium containing single stranded nucleic acids and double-stranded nucleic acids, comprising contacting the medium with a magnetisable solid phase support or substrate derivatised with single stranded nucleic acids having random sequences of nucleotide bases, whereby the former one or more single stranded nucleic acids anneal to the nucleic acids with which the solid phase support or substrate is derivatised, and then by means of a magnet, removing the solid phase support or substrate from the medium or concentrating and immobilizing it in a portion of the medium leaving the remainder of the medium free of the support or substrate, whereby the medium or the remainder

of the medium can be assayed for the presence of nucleic acids which have not annealed to the nucleic acids with which the support has been derivatised.

1/2




FIG. 1




FIG. 2A




FIG. 2B

2/2




FIG.3A



FIG.3B



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12Q 1/68</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/45554</b>
			<b>(43) International Publication Date:</b> 4 December 1997 (04.12.97)
<b>(21) International Application Number:</b> PCT/GB97/01487 <b>(22) International Filing Date:</b> 2 June 1997 (02.06.97) <b>(30) Priority Data:</b> 60/018,748      31 May 1996 (31.05.96)      US <b>(71) Applicant:</b> MOLECULAR SCIENCES LIMITED [GB/GB]; The Cedars, Watermill Lane, East Sussex TN34 4HY (GB). <b>(72) Inventors:</b> BRUCE, Ian, James; The Cedars, Watermill Lane, Pett, East Sussex TN35 4HY (GB). DAVIES, Martin, J.; 37 Ullswater Close, Bromley, Kent BR1 4JF (GB). <b>(74) Agent:</b> EDWARD EVANS & CO.; Chancery House, 53-64 Chancery Lane, London WC2A 1SD (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 9 April 1998 (09.04.98)	
<b>(54) Title:</b> CAPTURE OF SINGLE STRANDED NUCLEIC ACIDS			
<b>(57) Abstract</b>  A solid phase substrate derivatized with single stranded nucleic acids having random sequences of nucleotide bases and related method of capturing one or more single stranded nucleic acids by contacting with the solid phase substrate wherein the single stranded nucleic acids anneal to the nucleic acids of the substrate to result in the captured sequences.			
<div><div><p><b>AMPLIFICATION REACTION</b></p><p><b>REMOVAL OF CAPTURED SEQUENCES</b></p><p><b>ASSAY AMPLIFICATION PRODUCT</b></p><p><b>PRIMER</b></p></div></div>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/01487

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11530 A (UNIV BOSTON) 26 May 1994 see the whole document ---	1-15
X	WO 92 00091 A (BIOLIGAND INC) 9 January 1992 see the whole document ---	1-15
A	EP 0 278 220 A (ABBOTT LAB) 17 August 1988 ---	
A	WO 90 06042 A (HOLMES MICHAEL JOHN ; DYNAL AS (NO)) 14 June 1990 ---	
A	EP 0 296 557 A (DU PONT) 28 December 1988 ---	
A	WO 95 18868 A (ISIS PHARMACEUTICALS INC ; COOK PHILLIP DAN (US); ECKER DAVID J (US)) 13 July 1995 -----	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 February 1998

Date of mailing of the international search report

27/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Molina Galan, E

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. .onal Application No

PCT/GB 97/01487

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9411530 A	26-05-94	EP 0668932 A JP 8507199 T US 5503980 A US 5631134 A	30-08-95 06-08-96 02-04-96 20-05-97
WO 9200091 A	09-01-92	US 5650489 A AU 2836995 A AU 683762 B AU 2845495 A AU 659091 B AU 8238591 A CA 2086672 A EP 0542770 A IL 98682 A JP 6500308 T NZ 238805 A PL 168354 B PL 169616 B SK 407392 A US 5382513 A US 5510240 A	22-07-97 07-12-95 20-11-97 16-05-96 11-05-95 23-01-92 03-01-92 26-05-93 18-02-97 13-01-94 26-07-94 29-02-96 30-08-96 10-08-94 17-01-95 23-04-96
EP 0278220 A	17-08-88	AU 619170 B AU 1010688 A AU 630836 B AU 1082492 A DE 3876108 A ES 2052607 T JP 2690738 B JP 63245698 A	23-01-92 14-07-88 05-11-92 14-05-92 07-01-93 16-07-94 17-12-97 12-10-88
WO 9006042 A	14-06-90	AU 640626 B AU 4758690 A AU 634993 B AU 4759690 A CA 2003501 A CA 2003508 A DE 68908900 D DE 68908900 T DE 68913555 D	02-09-93 26-06-90 11-03-93 26-06-90 21-05-90 21-05-90 07-10-93 20-01-94 07-04-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/01487

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9006042 A		DE 68913555 T	07-07-94
		WO 9006045 A	14-06-90
		EP 0446260 A	18-09-91
		EP 0444120 A	04-09-91
		JP 4501956 T	09-04-92
		JP 4501959 T	09-04-92
		US 5512439 A	30-04-96
-----			
EP 0296557 A	28-12-88	AU 2084988 A	19-01-89
		DK 661089 A	23-02-90
		EP 0365595 A	02-05-90
		JP 2503983 T	22-11-90
		WO 8810313 A	29-12-88
-----			
WO 9518868 A	13-07-95	US 5587471 A	24-12-96
-----			